HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
Miguel Regueiro 1
Severine Vermeire 2
David T. Rubin 3
Marla C. Dubinsky 4
Ailsa L Hart 5
Joseph Wu 6
Jesse Green 7
John C. Woolcott 7
Kenneth J. Gorelick 7
Aoibhinn McDonnell 8
Krisztina Lazin 9
Laurent Peyrin-Biroulet 10, 11
1 Cleveland Clinic, Cleveland, United States
2 University Hospitals Leuven, Leuven, Belgium
3 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 St Mark’s Hospital, London, United Kingdom
6 Pfizer Inc, Groton, United States
7 Pfizer Inc, Collegeville, United States
8 Pfizer Ltd, Sandwich, Kent, United Kingdom
9 Pfizer AG, Zürich, Switzerland
10 University of Lorraine, CHRU-Nancy, Nancy, France
11 University of Lorraine, Inserm, NGERE, Nancy, France
Topic
IBD
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]